美股异动｜癌症药物开发商Revolution Medicines盘前跌9%，此前艾伯维否认收购传闻

Core Viewpoint - Revolution Medicines (RVMD.US) experienced a pre-market decline of 9%, trading at $93.47, following AbbVie's denial of acquisition discussions, which had previously been reported by the Wall Street Journal, estimating Revolution's valuation at $20 billion or higher [1] Group 1 - AbbVie has denied that it is in talks to acquire Revolution Medicines, countering earlier reports of in-depth discussions [1] - The valuation of Revolution Medicines was speculated to be around $20 billion or more, indicating significant market interest [1] - Revolution Medicines has stated that it will not comment on rumors or speculation in accordance with company policy [1]